How to log a compounded GLP-1 vial
Log a compounded GLP-1 vial by copying its label before the first injection: the concentration in mg/mL, the lot number, the beyond-use date, the storage instructions and the pharmacy's name, plus the date you first put a needle into it. Then record each injection in both units and mg, worked out from that concentration. Units on a syringe measure volume, not medicine, so the same number of units holds a different amount of semaglutide or tirzepatide in a vial of a different strength. FDA has received reports of patients injecting five to 20 times the intended amount, with confusion between milligrams, millilitres and units among the causes it names.
Compounded drugs are not FDA-approved, which means FDA does not review them for safety, effectiveness or quality before they are marketed. How much you inject is set by your prescriber and the pharmacy. This guide covers the record and the arithmetic you can use to check it; it does not cover where to get a compounded medicine.
What should you copy from the vial label?
| Record | Why it matters |
|---|---|
| Active ingredient, exactly as printed | Semaglutide or tirzepatide, including any salt name or added vitamin; FDA has raised concerns about both |
| Concentration (mg/mL) | Every unit-to-mg conversion depends on it. If the label gives a total, such as 10 mg in 2 mL, divide: 5 mg/mL |
| Total volume (mL) | Tells you roughly how many injections the vial holds |
| Lot number | Ties every injection, and any side effect, to one batch |
| Beyond-use date | The last date the pharmacy says the preparation can be used |
| Storage instructions | Refrigeration temperature, light, freezing |
| Pharmacy name and phone | Who to call with a question about the label or the instructions |
| The instructions as written | In units, mg or mL, word for word, with the syringe you were given |
| Date received, and its condition | FDA recommends not using an injectable GLP-1 that arrives warm or without enough refrigeration |
| Date first punctured | Starts the 28-day clock described below |
Write these on the vial's line in your log before you draw anything. If the label is hard to read or a field is missing, ask the pharmacy before the first injection, not after.
How do units and mg relate?
On a U-100 insulin syringe, 100 units is 1 mL, so 10 units is 0.1 mL. How much medicine that 0.1 mL holds depends on the vial:
- mg = units ÷ 100 × concentration (mg/mL)
- units = mg ÷ concentration × 100
The same 10 units from four different vials:
| Vial concentration | 10 units (0.1 mL) holds |
|---|---|
| 2.5 mg/mL | 0.25 mg |
| 5 mg/mL | 0.5 mg |
| 10 mg/mL | 1 mg |
| 25 mg/mL | 2.5 mg |
These are worked examples of the arithmetic, not doses. They show why a number of units means nothing until the concentration is written next to it.
FDA's July 2024 alert describes what goes wrong without it. In several reports, patients were told to draw 5 units (0.05 mL) and drew 50. In another, a provider meant to prescribe 0.25 mg, which was 5 units from that vial, and wrote 25 units instead: five times the intended amount. FDA encourages patients to talk with their health care provider or compounder about how to measure the intended dose.
To check the numbers on your own instructions, the units to mg calculator works for any concentration, and the semaglutide and tirzepatide calculators show the same sums for each medicine. If what you work out does not match the instructions, stop and call the pharmacy or prescriber before injecting. 0.3 mL, 0.5 mL and 1 mL syringes shows how the markings differ between syringe sizes, and mcg, mg, mL, units and IU explains each unit.
What is the beyond-use date, and what does 28 days mean?
A compounded medicine carries a beyond-use date (BUD) set by the pharmacy, rather than a manufacturer's expiry date. A multi-dose vial has a second limit once it has been opened:
- FDA says it generally recommends that vials containing multiple doses of sterile medicines be used within 28 days after the first use, because the risk of contamination rises after that. It recommends discarding the vial within 28 days after first use "even if medication remains in the vial", and not continuing to use it after 28 days "even if instructions from the compounder say the medication can be used for longer".
- CDC guidance for clinics says the same thing from the other side: once a multi-dose vial is opened (needle-punctured), it should be dated and discarded within 28 days unless the manufacturer states another date, and the beyond-use date should never exceed the original expiration date.
So log both dates. Write the first-puncture date on the vial's line and the date 28 days later beside the BUD; under FDA's recommendation the vial's last day is whichever comes first. FDA also says to use a new, sterile needle and syringe for every injection. How to track peptide vials, lot numbers and expiry dates covers the inventory side.
How should you log each injection from the vial?
| Date and time | Units | mg | Vial | Site |
|---|---|---|---|---|
| Sun 2 Nov, 8:00 am | As instructed | Units ÷ 100 × mg/mL | Lot from label, 5 mg/mL | Abdomen, left |
| Sun 9 Nov, 8:10 am | As instructed | As above | Same lot | Abdomen, right |
Writing both numbers means the record still makes sense if the concentration changes, and your prescriber can read it in the mg they think in. Note any injection where you were unsure of the amount, and what you did about it.
What should you note when the pharmacy changes the concentration?
A refill can arrive at a different strength from the last vial, and FDA notes that a single compounder may offer several concentrations. When that happens:
- Start a new vial line with the new concentration, lot, BUD and puncture date. Do not edit the old one.
- Redo the arithmetic. For the same amount in mg, the units change: new units = old units × old concentration ÷ new concentration. For example, 25 units of a 10 mg/mL vial is 2.5 mg, which is 12.5 units of a 20 mg/mL vial; drawing 25 units from the new vial out of habit would be twice as much. The vial switch calculator does this step.
- Get the new instructions confirmed by the pharmacy or prescriber before the first injection from the new vial, and log who confirmed them and when.
- Watch the next few weeks. Record any side effects with their day after the injection; how to keep a GLP-1 side effect diary shows the format.
If a vial arrives looking different from the last one, with damaged packaging or no instructions, FDA lists this among its warning signs. Note it and contact the pharmacy before using it.
What if too much was injected?
The Medication Guides for the FDA-approved semaglutide and tirzepatide products say that if you take too much, you should "call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away." FDA's alert lists severe nausea, severe vomiting and severe low blood sugar among overdose effects, and notes that semaglutide's half-life of about one week can mean a long period of observation. Once you are safe, log what happened, and consider reporting the error to FDA through MedWatch, which FDA encourages for medication errors with compounded semaglutide.
Doing it in PeptideMate
Add each vial in the Vials tab with its strength, lot number, expiry and storage, then log injections in the dose log, where the history shows the amount and the syringe units for each entry. The free printable peptide log sheet has a vial record page if you prefer paper. For brand-specific notes, see the semaglutide and tirzepatide tracker pages.
Common questions
Why log mg as well as units?
Because units only mean something next to a concentration. A log that says "10 units" is ambiguous the day a new vial arrives at a different strength; "10 units, 0.5 mg, 5 mg/mL, lot 1234" is not.
Does PeptideMate tell me how much to draw?
No. PeptideMate records the numbers you enter, and the calculators show the arithmetic. The amount comes from your prescriber and pharmacy.
Is a compounded vial the same as Ozempic or Mounjaro?
No. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed. The approved products come in pens or vials with fixed strengths printed on their labels.
Sources
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, US Food and Drug Administration, July 2024.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss, US Food and Drug Administration, content current as of 1 October 2026.
- Preventing unsafe injection practices, US Centers for Disease Control and Prevention.
- Ozempic (semaglutide) injection: prescribing information and Medication Guide, Novo Nordisk, via DailyMed (US National Library of Medicine), revised May 2026.
- Mounjaro (tirzepatide) injection: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed (US National Library of Medicine), revised August 2026.
- MedWatch: the FDA safety information and adverse event reporting program, US Food and Drug Administration.
This guide is about record keeping and unit arithmetic. It is not medical advice. See the medical disclaimer.